Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates

Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology

Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and pathophysiological investigations. This review highlights key collaborations between Pfizer and academic institutions in inflammation and immunology research, including dermatology, gastroenterology, rheumatology, and autoimmunity. These collaborations harness and enhance the development of innovative disease models, large clinical databases, registries, and novel clinical trial designs, and open new avenues in disease management to improve patient outcomes.

Immunohistochemical investigation of transient receptor potential melastatin-2 and spexin immunoreactivity in atopic dermatitis and mycosis fungoides

BACKGROUND

Atopic dermatitis (AD) is a chronic, pruritic, and inflammatory dermatosis seen in individuals with an atopic predisposition. This study aimed to examine the immunoreactivity of spexin and TRPM2 in skin samples from patients with AD and MF lesions using immunohistochemical methods.

MATERIALS AND METHODS

The study utilized a total of 60 skin samples, comprising 20 from AD patients, 20 from MF patients, and 20 from control subjects. Skin samples from patients diagnosed with other dermatological diseases, malignancies, and diabetes mellitus were excluded from the study. During staining, the prevalence (0.1: <25%, 0.4: 26-50%, 0.6: 51-75%, 0.9: 76-100%) and intensity (0: none, + 0.5: very low, + 1: low, + 2: moderate, + 3: intense) of immunoreactivity were used as criteria to establish a histo-score. Calculations employed the formula histo-score = prevalence x intensity.

RESULTS

Statistically significant higher spexin histoscores were observed in both the AD and MF patient groups compared to the control group (1.30 ± 0.46, 1.04 ± 0.29, and 0.20 ± 0.07, respectively; p = 0.000). Similarly, TRPM2 histoscores were significantly higher in the AD and MF patient groups compared to the control group (1.12 ± 0.28, 1.02 ± 0.30, and 0.20 ± 0.07, respectively; p = 0.000).

CONCLUSION

It is hypothesized that the increase in the neuropeptide spexin in both AD and MF is triggered by inflammation and contributes to itching mechanisms via galanin receptors. TRPM2, an ion channel, is speculated to be a marker of Reactive Oxygen Species (ROS) in chronic inflammatory dermatoses like AD, but it may not serve as a potential biomarker for distinguishing chronic inflammatory dermatoses from MF.

Lymphomatoid Papulosis With DUSP22 Rearrangement in a Patient With a Historical Diagnosis of Primary Cutaneous Anaplastic Large Cell Lymphoma

Lymphomatoid papulosis (LyP) with DUSP22 rearrangement is an uncommon subtype of lymphomatoid papulosis featured histologically by two distinct patterns of epidermotropic cells, weakly CD30+ small- to medium-sized T-cells and a dermal infiltrate of strongly CD30+ medium- to large-sized T-cells. DUSP22 rearrangement is detected more frequently in anaplastic large cell lymphoma (ALCL) than in LyP. Primary cutaneous anaplastic large cell lymphoma (pcALCL) cases can also show a similar biphasic CD30 staining pattern. LyP with DUSP22 rearrangement has a more indolent clinical course than pcALCL and is more likely to regress without treatment. Herein, we report a unique case of LyP with DUSP22 rearrangement diagnosed in an 81-year-old female with a historical diagnosis of pcALCL, made 20 years prior.

Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues

INTRODUCTION

Primary cutaneous lymphomas, notably mycosis fungoides (MF), present diagnostic challenges in recognizing early mycosis fungoides (eMF) due to their diverse clinical and histopathologic manifestations. The aim of our study was to use adjunctive histopathologic and immunohistochemical methods in eMF cases to make an early diagnosis and to facilitate differentiation from other dermatoses.

METHODS

This retrospective study analyzed 35 cases of eMF diagnosed at a single center. Demographic and clinicopathologic data were collected, and histopathologic features were assessed. Comparative analyses were conducted with conditions mimicking eMF, including large plaque parapsoriasis (LPP), psoriasis, and chronic dermatitis. Immunohistochemistry for T-cell markers (CD3, CD4, CD8, CD2, CD7) was performed.

RESULTS

With the scoring we applied in our study, a sensitivity of 91.43% (95% CI; 76.94% to 98.20%) and specificity of 85.71% (95% CI; 69.74% to 95.19%) for distinguishing eMF from LPP. Epidermotropism emerged as a crucial histopathologic marker, with a notable absence in most cases of cutaneous dermatitis (81.6% and 80% for CD and psoriasis, respectively) (P < 0.001). Immunohistochemistry revealed a T-helper phenotype (CD4+/CD8-) in the majority of eMF cases (78.1%), while CD4+/CD8+ and CD8+/CD4- patterns were less common (28.5% and 8.5%, respectively).

CONCLUSION

This study underscores the complexities in distinguishing eMF from inflammatory skin diseases, advocating for a comprehensive diagnostic approach.

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarises the clinical evidence supporting the current treatment options for these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.

Emerging concepts in dermatopathology: a special issue of neoplastic, inflammatory, and special-site dermatopathology and important practice considerations

This special issue of Human Pathology, highlighting updates in dermatopathology, represents a carefully curated collection of articles written by authors invited for their respective areas of expertise. This issue covers a range of important topics in neoplastic, inflammatory, or special-site dermatopathology, with an emphasis on "high-stakes" or emerging diagnoses or those that would be otherwise encountered infrequently by most practicing pathologists. In addition, topics important in clinical practice, including considerations relating to skin of color and cognitive bias in dermatopathology, are addressed. Throughout this issue, authors have incorporated scientific advances and recent literature to help pathologists tackle these difficult areas in dermatopathology.